Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT Booster Response and Persistence in Children
NCT01777308Phase 3Completed
- Sponsor
- GSK
- Start
- May 2013
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal group A, C, W135 and Y conjugate vaccine in meningococcal infection (2 arms), sponsored by GSK. Primary endpoint: Number of Subjects With Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroup A, C, W-135 and Y. Started May 2013; status: completed.
02
Drugs
meningococcal group A, C, W135 and Y conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT01777308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777308.